Rajapaksa, Naomi S. published the artcileDiscovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity, Application In Synthesis of 35112-05-1, the main research area is preparation benzolactam IRAK4 inhibitor structure.
IRAK4 kinase activity transduces signaling from multiple IL-1Rs and TLRs to regulate cytokines and chemokines implicated in inflammatory diseases. As such, there is high interest in identifying selective IRAK4 inhibitors for the treatment of these disorders. We previously reported the discovery of potent and selective dihydrobenzofuran inhibitors of IRAK4. Subsequent studies, however, showed inconsistent inhibition in disease-relevant pharmacodynamic models. Herein, we describe application of a human whole blood assay to the discovery of a series of benzolactam IRAK4 inhibitors. We identified potent mol. 19 which achieves robust in vivo inhibition of cytokines relevant to human disease.
ACS Medicinal Chemistry Letters published new progress about Enzyme inhibitors (IRAK4). 35112-05-1 belongs to class chlorides-buliding-blocks, name is 4-Chloro-2-fluoro-5-nitrobenzoic acid, and the molecular formula is C7H3ClFNO4, Application In Synthesis of 35112-05-1.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics